In the PD models, GLP1R agonists reduced the expression of proinflammatory cytokines and the degeneration of dopaminergic neurons, prevented cognitive impairment, and prolonged lifespan [25,26,27,28]. This evidence concerns the gene GLP1R and Parkinson disease.